Yanelda García-Vega

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, Meiby Rodríguez-González et al. · Vaccine · 2022 · 38 citations · Full text

Vaccination, Vaccine Safety, Open Label Phase +6

Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study

Lorenzo Anasagasti-Angulo, Yanelda García-Vega, Silvia Barcelona-Perez et al. · BMC Cancer · 2009 · 34 citations · Full text

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

María Eugenia Toledo-Romaní, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez et al. · Med · 2022 · 30 citations · Full text

Vaccination, Vaccine Safety, Soberana Plus Vaccines +6

Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children

Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, Chaumey Rojas-Iriarte et al. · International Journal of Infectious Diseases · 2022 · 21 citations · Full text

Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers

Francisco Hernández‐Bernal, Idrian García‐García, Carlos Alberto González-Delgado et al. · Biopharmaceutics & Drug Disposition · 2005 · 17 citations · Full text